Investigational drug · Phase 2
AP203
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AP203"
First trial start
2023
Jul 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP203", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer (NSCLC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Esophageal Squamous Cell Carcinoma (ESCC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AP203" as an intervention, largest first.
AP Biosciences Inc.Industry
NCT05473156 · 168 participants (planned) · Start Jul 24, 2023 · Primary completion Dec 2026
Drug: AP203; AP203 · For: Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamous Cell Carcinoma (HNSCC) and 1 more
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
Huang PL, Kan HT, Hsu CH, et al. · J Transl Med 2023
- A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
Huang PL, Kan HT, Hsu CH, et al. · J Transl Med 2023
- Enhanced biological control of root-knot nematode, Meloidogyne incognita, by combined inoculation of cotton or soybean seeds with a plant growth-promoting rhizobacterium and pectin-rich orange peel.
Hassan MK, Lawrence KS, Sikora EJ, et al. · J Nematol 2021
- Gaps Analysis of Integrating Product Design, Manufacturing, and Quality Data in The Supply Chain Using Model-Based Definition.
Trainer A, Hedberg T, Feeney AB, et al. · Proc ASME Int Conf Manuf Sci Eng 2016
- Activator protein-1 is necessary for angiotensin-II stimulation of human adrenocorticotropin receptor gene transcription.
Naville D, Bordet E, Berthelon MC, et al. · Eur J Biochem 2001
Also in development for Locally Advanced or Metastatic Solid Tumors
- CVL237Phase 22 trials
Convalife (Shanghai) Co., Ltd. · Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
- YL202 should be intravenously infusedPhase 22 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC
- ASP388BPhase 21 trial
Astellas · Locally Advanced or Metastatic Solid Tumors
- BC3195Phase 21 trial
Biocity Biopharmaceutics Co., Ltd. · Locally Advanced or Metastatic Solid Tumors
- DA-4505Phase 21 trial
Dong-A ST Co., Ltd. · Locally Advanced or Metastatic Solid Tumors
- PTT-936Phase 21 trial
Pyrotech Therapeutics, Inc. · Locally Advanced or Metastatic Solid Tumors
- XZP-5955Phase 21 trial
Xuanzhu Biopharmaceutical Co., Ltd. · Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.